Pharma Business - August 25, 2026
FDA proposes reclassifying Photocure’s blue light cystoscopy systems
The US FDA has proposed reclassifying blue light cystoscopy (BLC) systems used with Photocure's imaging agent Cysview for bladder cancer detection from Class III to Class II, a move the Norwegian medtech company says will support wider adoption of the technology in US hospitals.
Biotech Business - August 21, 2026
Hansa Biopharma prepares for US listing
The company has announced confidential submission of draft registration statement to the SEC to allow for a potential listing of ADSs in the United States.
Financing - August 20, 2026
Pixelgen Technologies raises USD 15.5 million
Pixelgen Technologies has closed an oversubscribed USD 15.5 million Series B financing to accelerate global commercialization of its Proxiome Kit and expand the company’s presence in key markets.
Financing - August 20, 2026
Lundbeck reports 16% revenue growth in first half of 2026
The company reported a 16% increase in revenue at constant exchange rates in the first six months of 2026, driven mainly by continued growth in Vyepti and Rexulti.
Agreement - August 20, 2026
SynAct signs term sheet for Brazilian dengue partnership
SynAct Pharma has signed a term sheet with Brazilian pharmaceutical company Hipolabor to co-develop and commercialize resomelagon for dengue and other viral infections in Brazil.
Pharma Business - August 18, 2026
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
Hansa Biopharma has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).